KR20080049758A - 통증 치료용으로 사용되는 피리다지논 유도체 - Google Patents

통증 치료용으로 사용되는 피리다지논 유도체 Download PDF

Info

Publication number
KR20080049758A
KR20080049758A KR1020087007056A KR20087007056A KR20080049758A KR 20080049758 A KR20080049758 A KR 20080049758A KR 1020087007056 A KR1020087007056 A KR 1020087007056A KR 20087007056 A KR20087007056 A KR 20087007056A KR 20080049758 A KR20080049758 A KR 20080049758A
Authority
KR
South Korea
Prior art keywords
substituted
unsubstituted
hydrogen
methylphenyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087007056A
Other languages
English (en)
Korean (ko)
Inventor
히토시 야마자키
치요시 가사하라
히로카즈 쿠보타
토루 곤타니
토루 아사노
히데카즈 미즈하라
마사하루 요코모토
케이지 미스미
토모히코 키노시타
Original Assignee
아스텔라스세이야쿠 가부시키가이샤
와쿠나가 세이야쿠 가부시키 가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스텔라스세이야쿠 가부시키가이샤, 와쿠나가 세이야쿠 가부시키 가이샤 filed Critical 아스텔라스세이야쿠 가부시키가이샤
Publication of KR20080049758A publication Critical patent/KR20080049758A/ko
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020087007056A 2005-09-01 2006-08-31 통증 치료용으로 사용되는 피리다지논 유도체 Ceased KR20080049758A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71282505P 2005-09-01 2005-09-01
US60/712,825 2005-09-01

Publications (1)

Publication Number Publication Date
KR20080049758A true KR20080049758A (ko) 2008-06-04

Family

ID=37607561

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087007056A Ceased KR20080049758A (ko) 2005-09-01 2006-08-31 통증 치료용으로 사용되는 피리다지논 유도체

Country Status (13)

Country Link
US (1) US20090042856A1 (enExample)
EP (1) EP1919919A1 (enExample)
JP (1) JP5066516B2 (enExample)
KR (1) KR20080049758A (enExample)
CN (1) CN101268079B (enExample)
AU (1) AU2006285599A1 (enExample)
BR (1) BRPI0617100A2 (enExample)
CA (1) CA2620740A1 (enExample)
IL (1) IL189697A0 (enExample)
NO (1) NO20081572L (enExample)
RU (1) RU2008112290A (enExample)
TW (1) TW200745034A (enExample)
WO (1) WO2007026950A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200904421A (en) 2007-05-03 2009-02-01 Astellas Pharma Inc New compounds
EP2170337A4 (en) 2007-06-28 2013-12-18 Abbvie Inc NEW TRIAZOLOPYRIDAZINE
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
CN104277004B (zh) * 2010-09-08 2016-08-24 住友化学株式会社 制备哒嗪酮化合物的方法和其中间体
EP2763987B1 (en) 2011-10-06 2018-07-18 Bayer CropScience AG Heterocyclylpyri(mi)dinylpyrazole as fungicidals
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
BR112015025260B1 (pt) 2013-04-25 2021-11-03 Beigene, Ltd Compostos heterocíclicos fundidos como inibidores da proteína quinase, sua composição, combinação e uso
RS63571B9 (sr) 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-pd1 antitela i njihova primena kao terapeutska i dijagnostička sredstva
JP6525437B2 (ja) 2014-04-02 2019-06-05 インターミューン, インコーポレイテッド 抗線維性ピリジノン
US10544225B2 (en) 2014-07-03 2020-01-28 Beigene, Ltd. Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
CN111153859B (zh) * 2015-04-15 2021-09-03 江苏恩华药业股份有限公司 哒嗪酮类衍生物及其应用
WO2018007885A1 (en) 2016-07-05 2018-01-11 Beigene, Ltd. COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
JP7402685B2 (ja) 2016-08-16 2023-12-21 ベイジーン スウィッツァーランド ゲーエムベーハー (s)-7-(1-アクリロイルピペリジン-4-イル)-2-(4-フェノキシフェニル)-4,5,6,7-テトラ-ヒドロピラゾロ[1,5-a]ピリミジン-3-カルボキサミドの結晶形、その調製、及びその使用
AU2017313085B2 (en) 2016-08-19 2024-06-20 Beone Medicines I Gmbh Use of a combination comprising a Btk inhibitor for treating cancers
AU2017319500C1 (en) 2016-08-31 2022-10-20 Les Laboratoires Servier Inhibitors of cellular metabolic processes
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
CN110461847B (zh) 2017-01-25 2022-06-07 百济神州有限公司 (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
TW202332436A (zh) 2017-04-18 2023-08-16 美商塞爾基因定量細胞研究公司 治療用化合物
WO2019001417A1 (en) 2017-06-26 2019-01-03 Beigene, Ltd. IMMUNOTHERAPY FOR HEPATOCELLULAR CARCINOMA
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3692144A1 (en) 2017-10-05 2020-08-12 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of dux4
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
WO2020249001A1 (zh) 2019-06-10 2020-12-17 百济神州瑞士有限责任公司 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
AU4431000A (en) * 1999-05-12 2000-12-05 Fujisawa Pharmaceutical Co., Ltd. Novel use
AUPQ441499A0 (en) * 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
WO2006038734A1 (en) * 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors

Also Published As

Publication number Publication date
BRPI0617100A2 (pt) 2011-07-12
CN101268079A (zh) 2008-09-17
CA2620740A1 (en) 2007-03-08
IL189697A0 (en) 2008-06-05
TW200745034A (en) 2007-12-16
CN101268079B (zh) 2011-09-14
WO2007026950A1 (en) 2007-03-08
EP1919919A1 (en) 2008-05-14
NO20081572L (no) 2008-03-31
JP2009507758A (ja) 2009-02-26
US20090042856A1 (en) 2009-02-12
RU2008112290A (ru) 2009-10-10
JP5066516B2 (ja) 2012-11-07
AU2006285599A1 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
KR20080049758A (ko) 통증 치료용으로 사용되는 피리다지논 유도체
AU2019216728B2 (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of Btk activity
JP4513919B2 (ja) ジヒドロピラゾロピリミジノン誘導体
CN117651700A (zh) 2-氨基苯并噻唑化合物及使用方法
TW202246255A (zh) Cdk抑制劑及其使用方法
CN118715215A (zh) 作为突变kras蛋白抑制剂的喹唑啉化合物及其用途
US20240109891A1 (en) Novel substituted tricyclic aza-heterocycles as sos1 inhibitors
JP2012511502A (ja) ジヒドロピリミドピリミジン誘導体
AU2012213390A1 (en) New azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
MX2014008913A (es) Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
JP2020527174A (ja) Atrキナーゼの複素環式阻害剤
US20230406860A1 (en) Heterocyclic spiro compounds and methods of use
JP2013533868A (ja) タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用
US20230192699A1 (en) Compounds as casein kinase inhibitors
KR20220163955A (ko) 보체 억제제로서의 피롤로피리미딘 아민
WO2016045598A1 (zh) 4-取代吡咯并[2,3-d]嘧啶化合物及其用途
KR101737724B1 (ko) 브루톤 티로신 키나아제의 억제제
HK1124603A (en) Pyridazinone derivatives used for the treatment of pain
KR20230171440A (ko) 약학적 화합물
NZ624021B2 (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity
KR20160095167A (ko) 헤테로환형 화합물

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080324

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110824

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130420

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20131031

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130420

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I